Brief: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation For Phase 2B Study Of Varoglutamstat
23/06/2022 06:05
June 23 (Reuters) - VIVORYON THERAPEUTICS NV 05Y.F :
* VIVORYON THERAPEUTICS N.V.: VIVORYON THERAPEUTICS N.V.
REPORTS
POSITIVE INDEPENDENT DATA SAFETY MONITORING BOARD RECOMMENDATION
FOR PHASE 2B STUDY OF VAROGLUTAMSTAT IN AD
* DSMB RECOMMENDS THAT STUDY SHOULD PROCEED WITH A MAXIMUM
DOSE OF
600 MG BID VAROGLUTAMSTAT OR PLACEBO
* PARALLEL GROUP, DOSE-FINDING PART OF STUDY COMPLETED
* DECISION BASED ON SAFETY DATA FROM 181 PATIENTS
* DETAILED STUDY RESULTS TO BE PRESENTED AT AN UPCOMING
MEDICAL
CONFERENCE
Source text for Eikon: ID:nEQW06fwa
Further company coverage: 05Y.F
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Vivoryon Therapeutics NV
See all newsEurope Research Roundup: Colonial, Covivio SA, Fluidra SA
Brief: Vivoryon Therapeutics Says VIVIAD Phase 2B Study Does Not Meet Primary Endpoints
Brief: Vivoryon Reports Positive Outcome To Proceed With Alzheimer Drug Study
Jefferies starts Vivoryon at 'buy' on positive risk/reward from Alzheimer's pill
Brief: Vivoryon Therapeutics Announces Proposed Appointment Of Frank Weber As Chief Executive Officer